Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report (ENG)

The neurophysiological and clinical results obtained in this patient suggest that switching therapy from a complexing protein-containing product to a product potentially free of complexing proteins, which has low immunogenicity, may be a viable therapeutic option in secondary non-responder patients.
Автор:  Santamato A, Ranieri M, Panza F, Frisardi V, Micello MF, Filoni S, Fiore P.
Год публикации:  2012
Файл:  Загрузить